67th Annual Meeting of the American Academy of Dermatology: San Francisco, California, USA, 610 March 2009

American Journal of Clinical Dermatology

Volumn 10, Issue 3, 2009, Pages 205-210

  Fraser, Kathy ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; ACANYA; ACZONE; ADALIMUMAB; ANTI ACNE AGENT; ANTIINFECTIVE AGENT; APRELIMAST; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CEFTOBIPROLE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DAPSONE; DAPTOMYCIN; EFALIZUMAB; EPIDUO; ETANERCEPT; ICLAPRIM; INFLIXIMAB; ISOTRETINOIN; LINEZOLID; METHOTREXATE; MINOCYCLINE; PHOSPHODIESTERASE IV INHIBITOR; PSEUDOMONIC ACID; RETAPAMULIN; RETINOID; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VOCLOSPORIN;

ACNE; ACTINIC KERATOSIS; ARTHRALGIA; BLASTOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; DERMATOLOGY; DOSAGE SCHEDULE COMPARISON; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; IMPETIGO; INJECTION SITE REACTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

ACNE VULGARIS; DERMATOLOGY; HEMANGIOMA; HUMANS; KERATOSIS, ACTINIC; MELANOMA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PROPRANOLOL; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SOCIETIES, MEDICAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 64849095423     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200910030-00009     Document Type: Conference Paper

References (30)

1. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580-92
2. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675-84
3. Griffiths C, Menter A, Strober B, et al. A phase III, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis [poster no. 3318]. J Am Acad Dermatol 2009; 60 (3): AB166
4. Kimball AB, Gordon KB, Langley RG, et al., ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144 (2): 200-7
5. Kimball A, Zhong J, Valdes J, et al. Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results froma phase II trial [poster no. 3326]. J Am Acad Dermatol 2009; 60 (3): AB168
6. Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008; 118 (9): 3151-9
7. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24 (5): 1529-38
8. Papp K, Bissonnette R, Rosoph L, etal. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008; 371 (9621):1337-42
9. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6 (4): 428-35
10. Gottschalk RW, Johnson LA. Calcitriol 3 micrograms/g versus calcipotriol 50 micrograms/g for plaque psoriasis: treatment, maintenance and cost [poster no. 2720]. J Am Acad Dermatol 2007; AB179
11. Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg/g ointment and calcipotriol 50 microg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148 (2): 326-33
12. Paller AS, Siegfried EC, Langley RG, et al., Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358 (3): 241-51
13. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66 (5): 670-5
14. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32 (7): 1213-8
15. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infection presenting as a periumbilical folliculitis. Cutis 2006; 77 (4): 229-32
16. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007; 67 (10): 1483-512
17. Zhanel GG, Lam A, Schweizer F, et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9 (4): 245-54
18. Yang LPH, Kearn SJ. Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections. Am J Clin Dermatol 2008; 9 (6):411-3
19. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59 (5): 792-800
20. Draelos ZD, Carter E, Maloney JM, et al., United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel,5%for the treatmentofacne vulgaris.JAmAcad Dermatol 2007; 56 (3): 439.e1-10
21. Thiboutot DM, Weiss J, Bucko A, et al., Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57 (5): 791-9
22. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4 (12): 813-31
23. Alexiades-Armenakas M. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol 2006; 5 (1): 45-55
24. Moloney FJ, Collins P. Randomized double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevu-linic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157 (1): 87-91
25. Szeimies R-M, Bichel J, Ortonne J-P, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008; 159 (1):205-10
26. Dudek AZ, Mescher MF, Okazaki I, et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol 2008; 31 (2): 173-81
27. Testori A, Richards J, Whitman E, et al., C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. Clin Oncol 2008; 26 (6):955-62
28. Léauté-Labrèze C, Dumas de La Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24): 2649-51
29. Bonifazi E, Colonna V, Mazzotta F, et al. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol 2008; 18 (3): 185-92
30. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy [letter]. NEnglJ Med 2008; 359 (26): 2846; author reply2846-7